Your browser doesn't support javascript.
loading
Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance
Hannah Wang; Jacob Miller; Michelle Verghese; Mamdouh Sibai; Daniel Solis; Kenji O Mfuh; Becky Jiang; Naomi Iwai; Marilyn Mar; ChunHong Huang; Fumiko Yamamoto; Malaya K. Sahoo; James Zehnder; Benjamin A. Pinsky.
Afiliación
  • Hannah Wang; Stanford University School of Medicine
  • Jacob Miller; Stanford University School of Medicine
  • Michelle Verghese; Stanford University School of Medicine
  • Mamdouh Sibai; Stanford Healthcare
  • Daniel Solis; Stanford Medicine
  • Kenji O Mfuh; Stanford Health Care
  • Becky Jiang; Stanford Health Care
  • Naomi Iwai; Stanford Health Care
  • Marilyn Mar; Stanford Health Care
  • ChunHong Huang; Stanford University School of Medicine
  • Fumiko Yamamoto; Stanford University School of Medicine
  • Malaya K. Sahoo; Stanford University School of Medicine
  • James Zehnder; Stanford University School of Medicine
  • Benjamin A. Pinsky; Stanford University School of Medicine
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21255480
ABSTRACT
BackgroundEmergence of SARS-CoV-2 variants with concerning phenotypic mutations is of public health interest. Genomic surveillance is an important tool for pandemic response, but many laboratories do not have the resources to support population-level sequencing. We hypothesized that a spike genotyping nucleic acid amplification test (NAAT) could facilitate high-throughput variant surveillance. MethodsWe designed and analytically validated a one-step multiplex allele-specific reverse transcriptase polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein mutations (L452R, E484K, N501Y). Assay specificity was validated with next-generation whole-genome sequencing. We then screened a large cohort of SARS-CoV-2 positive specimens from our San Francisco Bay Area population. ResultsBetween December 1, 2020 and March 1, 2021, we screened 4,049 unique infections by genotyping RT-qPCR, with an assay failure rate of 2.8%. We detected 1,567 L452R mutations (38.7%), 34 N501Y mutations (0.84%), 22 E484K mutations (0.54%), and 3 (0.07%) E484K+N501Y mutations. The assay had near-perfect (98-100%) concordance with whole-genome sequencing in a validation subset of 229 specimens, and detected B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants, among others. The assay revealed rapid emergence of L452R in our population, with a prevalence of 24.8% in December 2020 that increased to 62.5% in March 2021. ConclusionsWe developed and clinically implemented a genotyping RT-qPCR to conduct high-throughput SARS-CoV-2 variant screening. This approach can be adapted for emerging mutations and immediately implemented in laboratories already performing NAAT worldwide using existing equipment, personnel, and extracted nucleic acid. Summary / Key PointsEmergence of SARS-CoV-2 variants with concerning phenotypes is of public health interest. We developed a multiplex genotyping RT-qPCR to rapidly detect L452R, E484K, and N501Y with high sequencing concordance. This high-throughput alternative to resource-intensive sequencing enabled surveillance of L452R emergence.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Diagnostic_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Diagnostic_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint